ALK and non-small cell lung carcinoma: It was clearly demonstrated that the expression imbalance technology has its value in increasing the sensitivity of the assay and thereby acts as the complement for detection of fusion transcripts with uncommon or novel fusion partners in NSCLC, especially in the case of ALK and RET fusions.